Inovio Strikes First Partnership, In Emerging Markets, For Lead Product

14 Feb 2017

Inovio's new licensing deal for its most advanced pipeline asset gives the US firm not only its first partner for the cervical dysplasia vaccine but also a presence in a major emerging market.

Beijing-based ApolloBio Corp. has acquired exclusive rights to develop and commercialize Inovio Pharmaceuticals Inc.'s cervical dysplasia DNA vaccine VGX-3100 in mainland China, Hong Kong, Macau and Taiwan.

The new deal, worth $15m in upfront and near-term payments, gives Plymouth Meeting, Pennsylvania-based Inovio its first partner for the...